Guillaume Luxardi

Re:Vision — United States

Medicine · Health Sciences

24h-index1.8kcitations89works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(24), CAR-T cell therapy research(18), Chronic Lymphocytic Leukemia Research(15), Psoriasis: Treatment and Pathogenesis(12), Glycosylation and Glycoproteins Research(8)

Publications89 total

A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis
Blood Advances·2025· 1 citedOpen Access
Super-resolution microscopy reveals a Rab6a-dependent trafficking hub for rhodopsin at the mammalian rod photoreceptor Golgi
Biology Open·2025· 1 citedOpen Access
Super-resolution microscopy reveals a Rab6a-dependent trafficking hub for rhodopsin at the mammalian rod photoreceptor Golgi
2025Open Access
Hypoglycemia promotes inner blood-retinal barrier breakdown and retinal vascular leakage in diabetic mice
Science Translational Medicine·2025· 5 cited
A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations
JTO Clinical and Research Reports·2025Open Access
Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis
Blood Neoplasia·2025· 1 citedOpen Access
Stimulating the regenerative capacity of the human retina with proneural transcription factors in 3D cultures
Proceedings of the National Academy of Sciences·2025· 5 citedOpen Access
Stimulating the regenerative capacity of the human retina with proneural transcription factors in 3D cultures
2024· 1 citedOpen Access
Immune Cell Dynamics in EGFR-Mutated NSCLC Treated With Afatinib and Pembrolizumab: Results From a Phase IB Study
JTO Clinical and Research Reports·2024· 2 citedOpen Access
Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial
Nature Communications·2023· 17 citedOpen Access
Supplemenary Figure 6 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
2023Open Access
Supplementary Figure Legends from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
2023Open Access
Supplementary Methods from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
2023Open Access
Supplemenary Figure 6 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
2023Open Access
Data from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
2023Open Access
Supplemenary Figure 4 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
2023Open Access
Supplementary Figure 1 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
2023Open Access
Supplemenary Figure 7 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
2023Open Access
Supplementary Figure 3 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
2023Open Access
Supplemenary Figure 7 from A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Emanual Maverakis(29), Alexander A. Merleev(22), Alina I. Marusina(19), Stephanie T. Le(13), Michiko Shimoda(10), Carlito B. Lebrilla(9), Atrin Toussi(9), Laurent Kodjabachian(8), Fernando Ferreira(8), Min Zhao(8), Brian Reid(8), Iannis E. Adamopoulos(8), Jóhann E. Guðjónsson(8), Lam C. Tsoi(6), Gege Xu(5), William Liakos(5), Marie Cibois(4), Dayoung Park(4), Elizabeth A. Wang(4), Forum Patel(4)